FDA grants priority review to Merck’s supplemental biologics license application for Keytruda (pembrolizumab) monotherapy for third-line treatment of patients with advanced small cell lung cancer

Merck/MSD

20 February 2019 - Marks first application for Keytruda in SCLC.

Merck today announced that the U.S. FDA has accepted and granted priority review for a new supplemental biologics license application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with advanced small cell lung cancer (SCLC) whose disease has progressed after two or more lines of prior therapy. This sBLA, which is seeking accelerated approval for this new indication, is based on data from the SCLC cohorts of the Phase 2 KEYNOTE-158 and Phase 1b KEYNOTE-028 trials. 

The FDA has set a Prescription Drug User Fee Act, or target action, date of 17 June 2019.

Read Merck press release

Michael Wonder

Posted by:

Michael Wonder